258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818646203770863616 |
|---|---|
| author | Benjamin Vincent Dominic Moore Mark Woodcock Carey Anders Amanda Van Swearingen Maria Sambade Luz Cuaboy Amy Garrett Karen McKinnon Kristen Cowens Dante Bortone Benjamin Calhoun Lisa Carey Claire Dees Trevor Jolly Hyman Muss Katherine Reeder-Hayes Rebecca Kaltman Rachel Jankowitz Vinay Gudena Oludamilola Olajide Charles Perou Jonathan Serody |
| author_facet | Benjamin Vincent Dominic Moore Mark Woodcock Carey Anders Amanda Van Swearingen Maria Sambade Luz Cuaboy Amy Garrett Karen McKinnon Kristen Cowens Dante Bortone Benjamin Calhoun Lisa Carey Claire Dees Trevor Jolly Hyman Muss Katherine Reeder-Hayes Rebecca Kaltman Rachel Jankowitz Vinay Gudena Oludamilola Olajide Charles Perou Jonathan Serody |
| author_sort | Benjamin Vincent |
| collection | DOAJ |
| first_indexed | 2024-12-17T00:42:55Z |
| format | Article |
| id | doaj.art-66ceae14360c4fa2897157a5c2f6fcac |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-17T00:42:55Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-66ceae14360c4fa2897157a5c2f6fcac2022-12-21T22:09:59ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0258258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancerBenjamin Vincent0Dominic Moore1Mark Woodcock2Carey Anders3Amanda Van Swearingen4Maria Sambade5Luz Cuaboy6Amy Garrett7Karen McKinnon8Kristen Cowens9Dante Bortone10Benjamin Calhoun11Lisa Carey12Claire Dees13Trevor Jolly14Hyman Muss15Katherine Reeder-Hayes16Rebecca Kaltman17Rachel Jankowitz18Vinay Gudena19Oludamilola Olajide20Charles Perou21Jonathan Serody2219University of North Carolina, Chapel Hill, NC, USAPediatrics, University of Utah Health Care, Salt Lake City, Utah, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA2Duke University, Durham, NC, USA2Duke University, Durham, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA3George Washington University, Washington, DC, USA4University of Pittsburgh, Pittsburgh, PA, USA5Cone Health Cancer Center, Greensboro, NC, USA6Rex Hematology Oncology, Raleigh, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA1UNC Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA |
| spellingShingle | Benjamin Vincent Dominic Moore Mark Woodcock Carey Anders Amanda Van Swearingen Maria Sambade Luz Cuaboy Amy Garrett Karen McKinnon Kristen Cowens Dante Bortone Benjamin Calhoun Lisa Carey Claire Dees Trevor Jolly Hyman Muss Katherine Reeder-Hayes Rebecca Kaltman Rachel Jankowitz Vinay Gudena Oludamilola Olajide Charles Perou Jonathan Serody 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer Journal for ImmunoTherapy of Cancer |
| title | 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer |
| title_full | 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer |
| title_fullStr | 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer |
| title_full_unstemmed | 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer |
| title_short | 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer |
| title_sort | 258 scientific correlatives from lccc 1525 a phase ii study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer |
| work_keys_str_mv | AT benjaminvincent 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT dominicmoore 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT markwoodcock 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT careyanders 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT amandavanswearingen 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT mariasambade 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT luzcuaboy 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT amygarrett 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT karenmckinnon 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT kristencowens 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT dantebortone 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT benjamincalhoun 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT lisacarey 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT clairedees 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT trevorjolly 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT hymanmuss 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT katherinereederhayes 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT rebeccakaltman 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT racheljankowitz 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT vinaygudena 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT oludamilolaolajide 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT charlesperou 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer AT jonathanserody 258scientificcorrelativesfromlccc1525aphaseiistudyofaprimingdoseofcyclophosphamidepriortopembrolizumabtotreatmetastatictriplenegativebreastcancer |